Company news
Adma Biologics Inc (NASDAQ:ADMA) news
Adma Biologics Inc news releases on 6ix. Latest, Aug 7, 2026: ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit…
Press releases & updates
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
August 7, 2026
ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 5, 2026
ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026
July 29, 2026
ADMA BIOLOGICS, INC. Scott+Scott Attorneys at Law LLP Investigates ADMA Biologics, Inc.’s Directors and Officers for Breach of Fiduciary Duties – ADMA
June 29, 2026
ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
May 6, 2026
ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older
May 4, 2026
ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026
April 29, 2026
ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
March 26, 2026
ADMA Biologics Addresses Misleading Short-Seller Report
March 24, 2026
ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative
March 1, 2026
ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 25, 2026
ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
February 17, 2026
ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update
January 11, 2026
ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026
January 4, 2026
ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update
November 4, 2025
ADMA Biologics to Report Third Quarter 2025 Financial Results on November 5, 2025
October 28, 2025
ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update
August 5, 2025
ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025
July 29, 2025
ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
May 6, 2025
ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025
April 29, 2025
ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
April 27, 2025
ADMA Biologics Statement on Tariffs
April 6, 2025
ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 2, 2025
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
February 27, 2025
ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
February 24, 2025
ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update
January 12, 2025
ADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025
January 6, 2025
ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility
December 19, 2024
ADMA Biologics Announces Third Quarter 2024 Financial Results and Provides Business Update
November 6, 2024
ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024
October 28, 2024
ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference
September 9, 2024
ADMA Biologics Announces Partial Paydown of Revolving Credit Facility
August 13, 2024
ADMA Biologics Announces Second Quarter 2024 Financial Results and Provides Business Update
August 7, 2024
ADMA Biologics to Report Second Quarter 2024 Financial Results on August 8, 2024
July 31, 2024
ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update
May 8, 2024
ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024
May 1, 2024
ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®
March 10, 2024
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 27, 2024
ADMA Biologics Announces CFO Transition
February 27, 2024
ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
February 20, 2024
ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics
February 20, 2024
ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update
January 7, 2024
ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management
December 17, 2023
ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient Setting for Those 2 Years of Age and Older
December 11, 2023
ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD
November 15, 2023
ADMA Biologics Announces Third Quarter 2023 Financial Results and Provides Business Update
November 7, 2023
ADMA Biologics to Report Third Quarter 2023 Financial Results on November 8, 2023
October 31, 2023
ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update
August 8, 2023
ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023
August 1, 2023
ADMA BioCenters Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA
July 18, 2023